Bcl-2 inhibitor Navitoclax, Purity ≥98%

Synonym: 923564-51-6; Navitoclax; ABT-263; ABT-263 (Navitoclax); (R)-4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; Bcl-2 inhibitor

MDL: MFCD12756219
CAS Number: 923564-51-6
Compound CID: 24978538

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Navitoclax, soluble in DMSO and insoluble in ethanol and water, specifically inhibits the function of the anti-apoptotic proteins, thereby promoting apoptosis in cancer cells. It targets Bcl-xL, Bcl-2, Bcl-w, A1, and Mcl-1.

Molecular Weight

974.6

Molecular Formula

C₄₇H₅₅ClF₃N₅O₆S₃

Targets

Bcl-xL: ≤0.5 nM (Ki); Bcl-2: ≤1 nM (Ki); Bcl-w: ≤1 nM (Ki); A1: 354 nM (Ki); Mcl-1: 550 nM (Ki)

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 89 mg/mL (91.31 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Applications

Navitoclax can be used to study in the context of hematologic malignancies and some solid tumors.